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Abstract
Excessive visceral adiposity, hypothesized to be a key mediator in metabolic derangements, has recently been shown to exert toxic
effects on cardiac structure and function. Data regarding the mechanistic link between regional adiposity, left atrial (LA)
electromechanical remodeling, and heart failure with preserved ejection fraction (HFpEF) have been lacking.
Various visceral adiposity measures, including pericardial fat (PCF), thoracic periaortic (TAT) fat, regional inter-atrial fat (IAF), and
atrioventricular groove fat (AV Groove Fat), were assessed by multidetector computed tomography in 2 study cohorts (an annual
health survey cohort and an outpatient cohort). We related such measures to cardiometabolic profiles in health survey cohort and LA
electromechanical indices in our outpatient cohort, with Cox proportional hazards performed to examine the temporal trends of heart
failure (HF).
In our annual health survey cohort (n=362), all 4 adiposity measures were positively related to unfavorable anthropometrics and
systemic inflammation (high-sensitivity C-reactive protein) (all P<0.05). In addition, both greater IAF and AV Groove Fat were
positively associated with higher fasting glucose, HbA1c levels, and insulin resistance (all P<0.05). In the outpatient cohort, the
HFpEF group demonstrated the greatest adiposity measures, with greater IAF (≥8.2mm, hazard ratio: 4.11, 95% confidence interval:
1.50–11.32) associated with reduced LA strain (ß-coef: –0.28), higher LA stiffness (ß-coef: 0.23), and longer P wave duration (ß-coef:
0.23) in multivariate models (all P<0.05), and further related to higher HF hospitalization during follow-up.
We therefore propose a possible pathophysiologic link among greater visceral adiposity, systemic inflammation, cardiometabolic
risks, and HFpEF. Regional adiposity, especially IAF, was tightly linked to altered LA electromechanical properties and likely plays a
key role in HF prognosis.
Abbreviations: AF = atrial fibrillation, AV Groove Fat = atrio-ventricular Groove Fat, HFpEF = heart failure with preserved ejection
fraction, IAF = Inter-atrial fat, LA = left atrial/left atrium, MDCT = multidetector computed tomography, PCF = pericardial fat, TAT =
thoracic periaortic fat.
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1. Introduction
Preserved left atrial (LA) mechanical function is critical in
maintaining adequate cardiac filling and pump function in
subjects in sinus rhythm. Deteriorating LA function is a key
feature in the diagnosis of heart failure (HF) with preserved
ejection fraction (HFpEF),[1] and may be a clinical prognosticator
in this patient population.[2] Previous studies have demonstrated
that chronically elevated left ventricular (LV) filling pressures
may not fully explain LA mechanical failure or remodeling.[3,4]
Instead, several comorbid conditions including diabetes,
obesity, hypertension, or coronary artery disease can contribute
to LA fibrotic changes [3] and shared common clinical features
with HFpEF, which can be identified by lower values of LA
deformation.[5]
Hypertension-induced mechanical stretch can lead to ventric-
ular remodeling and hypertrophy, as well as atrial enlargement
and fibrosis,[6] resulting in HF. However, metabolic derange-
ments such as obesity and diabetes can cause HF,[7] driven in part
by the number of inflammatory signaling pathways super-
imposed on mechanical load.[8–10] In addition, both metabolic
disorders and systemic inflammation are linked to the onset of
atrial fibrillation (AF).[11]
Effective therapeutic approaches for patients with HFpEF
remain limited,[12] and further exploration of the pathophysio-
logical mechanisms and pathways involved is therefore needed
with a clinical perspective to more effective delivery of therapies.
A recent focus is the role of visceral adipose tissue as a key player
with important proinflammatory and biological mediators
associated with adverse cardiac electromechanical remodeling
and subclinical contractile dysfunction.[13–15]
Therefore, we thus speculated that visceral adiposity, especially
that in anatomic proximity to cardiac structures, not only plays a
central role in mediating inflammation and oxidative stress, but
may also trigger certain cardiac electromechanical disturbances
that are more accentuated in HFpEF.
2. Methods
2.1. Study populations
This study consisted of 2 phases. The first phase of study
comprised a cohort of patients who underwent annual health
check-ups (n=362, from January 2007 to August 2009). All
participants had routine physical examinations with baseline
demographic and anthropometric information obtained, as well
as detailed review of medical history. Biochemical data, routine
body surface electrocardiography (ECG), and computed tomog-
raphy (CT) were performed for cardiovascular disease charac-
terizationwith subspecialty referral if appropriate. For the second
phase of the study, we consecutively enrolled study subjects from
the cardiovascular outpatient clinic (n=206, from January 2010
to July 2011) at a tertiary care hospital in North Taiwan (Mackay
Memorial Hospital). Similarly, all participants underwent
anthropometric measures with biochemical data collected.
Routine ECG, echocardiography, and CT were also performed,
and the aim was to validate the associations between CT-defined
visceral adiposity and clinical cardiovascular risk profiles, and to
further examine whether such adiposity measures may discrimi-
nate individuals with high cardiovascular risks or those with
clinical evidence of HF.
For both study phases, body fat composition was assessed by
utilizing bioelectrical impedance analysis from foot-to-foot
impedance estimate using the Tanita-305 Body-Fat Analyzer
(Tanita Corp, Tokyo, Japan), which provided information about
whole body fat percentage in the standing position. For the
second phase of study, we further categorized them into healthy,
co-morbidity, and HFpEF groups. The final subjects enrolled
comprised those with known cardiovascular comorbidities (n=
108) and those who had HFpEF (n=58). The details of study
enrollment, including the definition of HF, eligibility, and
exclusion criteria were similar to those used in our previous
publication[16]; an additional 40 subjects without previous
diagnosis of any systemic disease in annual health check-ups
served as the healthy control group. The comorbidities group was
defined as those with any of the following clinical conditions:
hypertension, diabetes, obesity (defined as body mass index
[BMI] ≥30kg/m2), minor degree of renal insufficiency (defined as
estimated glomerular filtration rate [eGFR] <60mL/min/1.73
m2), history of cardiovascular diseases (stroke or coronary artery
disease), or any medication use for hyperlipidemia. This study
design was approved by the local ethics committee in accordance
with the Declaration of Helsinki (12MMHIS052).
2.2. CT-defined visceral adiposity: PCF, TAT, IAF, and AV
groove adipose tissue quantification
Multidetector CT (MDCT) study was performed using a Dual
Source CT scanner (Somatom Definition, Siemens Medical
Solutions, Forchheim, Germany) with 320.6mm per tube
with double sampling by z-flying focal spot, rotation time of 330
ms, tube voltage of 120kV, and full tube current of 625mA per
tube (independent of patient size).
Contrast injection (iopamiro 370mg/mL, Bracco, Italy) was
administered (60–85mL) at an injection rate of 5mL/s with a
delay calculated during the timing bolus scan. Overlapping
transaxial images were reconstructed using a medium sharp
convolution kernel (B25f) with an image matrix of 512512
pixels, slice thickness and increment of 0.75/0.4mm using an
ECG-gated half-scan algorithm. Image reconstruction was
retrospectively gated to ECG. Reconstructed image data were
transferred to a dedicated workstation (Aquarius 3D Worksta-
tion, TeraRecon, SanMateo, CA) for subsequent visceral adipose
tissue, pericardial fat (PCF), and thoracic periaortic (TAT)
analyses. The semiautomatic segmentation technique was
developed for quantification of fat volumes. We traced the
region of interest manually and defined fat tissue by using
Hounsfield units (HU) as pixels with the attenuation of 190 to
30 HU, which corresponded to adipose tissue in contrast-
enhanced cardiac CT scans.[17] PCF was defined as any adipose
tissue volume (unit: mL) located within the pericardial sac
(Fig. 1A). TAT tissue was defined as volume (unit: mL) of the
adipose tissue surrounding the thoracic aorta, which extended
67.5mm from the level of the bifurcation of pulmonary arteries as
start point, with cranial-caudal coverage of the thoracic aorta to
the diaphragm as its lower anatomical limit (Fig. 1B). For
acquiring the thickness of regional epicardial adipose tissue
(unit: mm), we further adjusted the imaging plane into horizontal
long-axis plane for the measurements of inter-atrial fat (IAF) and
atrioventricular (AV) groove fat (Fig. 1C). This approach has
been validated previously.[18]
We categorized the participants into 3 groups based on
metabolic scores as defined by NCEP ATP III criteria[19,20]: waist
circumference ≥80cm for women or ≥90cm for men (1 point);
serum fasting glucose concentration ≥100mg/dL (≥5.5mmol/L)
(1 point); serum high-density lipoprotein (HDL) level<40mg/dL
(<1.03mmol/L) for men or <50mg/dL (<1.29mmol/L) for
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women (1 point); serum triglyceride level >150mg/dL (>1.69
mmol/L) (1 point); and/or blood pressure >130/85mmHg (1
point). The metabolic score therefore ranged from 0 to 5 with
metabolic syndrome (MetS: defined as metabolic scores ≥3)
denoting higher risk for cardiometabolic profiles, which had been
shown to confer higher cardiovascular risks including HF in
previous studies.[10] Owing to a graded increase of cardiovascular
diseases risk based on previous research,[21] we therefore
categorized our study population in protocol 1 as metabolic
score 0 (reference category); metabolic scores 1–2; and metabolic
scores ≥3, defined as MetS.
2.3. Echocardiography protocol for assessing conventional
echocardiography parameters and diastolic indices
Transthoracic Doppler echocardiography examination was
performed on all subjects using a commercially available
ultrasound system (Vivid 7, GE Vingmed Ultrasound, Horten,
Norway) equipped with a 2 to 4MHz transducer (M4S).
Parameters including LA diameter, LV internal diameter, derived
LV mass, and LV mass index were determined from M-mode
measurements using American Society of Echocardiography
criteria.[21] The aortic root diameter was defined as the largest
end-diastolic diametermeasuredon the parasternal long-axis view.
LV end-diastolic and end-systolic volumes were further
quantified using the biplane Simpson method with ratio of LV
mass to volume calculated using LV mass divided by LV end-
diastolic volume. Assessment of LV diastolic function was
determined using pulsed-wave Doppler of transmitral inflow
velocities measured at the tip of the mitral leaflets with E/A ratio
assessed from early (E) and late diastolic (A) filling velocities.
Tissue Doppler imaging was used to determine the lateral mitral
annular velocities, measuring both the peak systolic (S’) and early
diastolic (E’) values. Left-sided ventricular filling pressures (E/E’)
were estimated using the ratio of the early (E) transmitral Doppler
velocity divided by the tissue Doppler imaging-derived early
diastolic (E’) lateral mitral annular velocity.
2.4. Assessment of systolic myocardial mechanics and LV
twist by speckle-tracking deformation imaging
Baseline 2-dimensional images (including 2-chamber, 4-chamber,
and apical long-axis views) for longitudinal strain and 3 short-
axis views (including mitral, papillary, and apical levels) were
Figure 1. (A, B) Measurements of total volume of peri-cardial fat tissue (PCF) and thoracic periaortic fat tissue (TAT). Orange color indicated PCF and TAT in axial,
sagital, coronal views, and 3-dimensional reconstructions. (C) Thickness of PCF in interatrial septum (solid line) and left atrioventricular groove (dotted line) was
measured in the horizontal long-axis view. (D) Left atrial (LA) deformation (LA strain, %) analysis by using 2-dimensional speckle-tracking technique and
corresponding curves were displayed.
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analyzed by offline endocardial border manual tracing, using
novel offline proprietary software (EchoPAC version BT11
workstation; GE VingMed Ultrasound) based on automated
speckle-tracking algorithms with an average frame rate estimated
between 60 and 80frames/s. The global longitudinal strain was
averaged from all 3 apical views (2-chamber, 4-chamber, and
apical long-axis views) and displayed parametrically as a
polar plot (bull’s-eye) map, with global circumferential and
radial strain curves obtained by averaging different values from
3 different short-axis levels, respectively. Cardiac twist was
generated automatically using the same software.
2.5. Assessment of LA electromechanical functions
Themaximal andminimal LAvolumeswere calculated fromapical
4-chamber and 2-chamber views just before mitral valve opening,
and at mitral valve closure using the modified biplane
2-dimensional echocardiography (Simpson’s method). During
image acquisition, care was taken to optimize visualization of the
LA cavity and to maximize LA area in apical views, avoiding
foreshortening of the left atrium. We further assessed LA
longitudinal systolic mechanical function (LA strain) by using
same offline workstation as LV 2-dimensional speckle-tracking
analysis from both apical 4- and 2-chamber views by the same
technician. Briefly, theLAendocardial borderwasmanually traced
at end-systole using a point-and-click approach in both apical
views. An epicardial surface tracing was automatically generated
by the software, delineating a region of interest including
6 segments. The region of interest was manually adjusted to
encompass the thickness of theLAmyocardium, and anautomated
segmental tracking quality analysis was obtained (Fig. 1D).
Minimal manual adjustment of the region of interest was
performed in the case of segments with inadequate tracking with
cine loop preview used to confirm that the inner tracking border
followed the LA endocardial border throughout the cardiac cycle.
The actual LA strain was derived as the average values of peak
systolic strain of all LA segments during LV systole (Fig. 1D).
Participants underwent routine 12-lead surface ECG studies by
using autonomic instruments (Page Writer Trim III, Phillip, 3000
MinutemanRoad,Andover,MA)with standard settings (25mm/s,
1mV/cm, and 100Hz) recorded for further analysis. Electrical
parameters including QRS or PR duration, and QT interval (with
or without correction for cycle length) were all obtained by
automatic software algorithm across the 12-lead tracing. Quanti-
tative assessments of P wave duration were performed by using
DICOM format image analysis software (Sante DICOM editor,
3.1.20)with thenearest 4msaspossible. In total, 2Pwaveduration
parameters, including original P wave maximum duration and
corrected P wave maximum duration (corrected for heart rate
based on Bazett’s formula as: P wave maximum duration/[RR]1/2)
from lead II, were evaluated in each study participant.[21]
2.6. Agreement of LA volume measures between
computed tomography and its association with LA strain
In total, 59 subjects, including 13 subjects from the normal
population, 35 subjects from comorbidity, and 11 subjects from
HFpEF groups were randomly chosen to have an echocardiog-
raphy-derived LA volume measurement (Biplane Simpson’s
method) during end-systolic phase (with maximal LA volume)
compared with the CT-defined LA volume measurement. The
correlation between these 2 measures in our laboratory was good
(r=0.94, P<0.001) with limits of agreement estimated to be:
–1.586 to 15.416 by Bland–Altman analysis.
2.7. Statistical analysis
Continuous data are reported as the mean± standard deviation
(SD) and compared using a nonparametric trend test (Wilcoxon
rank sum test) across ordered age groups with categorical or
proportional incidence data expressed as a proportion and
compared with use of the x2 or Fisher exact test, as appropriate.
One-way analysis of variance (ANOVA) was performed to test
the differences in the continuous data among the 3 groups with a
post hoc Bonferroni correction for paired comparisons. Because
LA dysfunction and remodeling depend largely on age and other
cardiovascular risk factors, an analysis of covariance was also
used to adjust for relevant covariates in the comparison of mean
values among the 3 groups. The minimum required samples
needed to detect significant difference between the HFpEF and
comorbidity groups by longitudinal LA deformation (strain), a
sensitive and powerful clinical marker for such purpose, was
calculated. A reported mean±SD of 19.9±7.3 in the HFpEF
group and 30.8±11.4 in the asymptomatic LV diastolic
dysfunction group with similar distribution of morbidities as
in our comorbidity group resulted in an effect size (Cohen’s d) of
0.563.[22] Given that the subjects with HFpEF had a smaller
amount with a potentially wide range of longitudinal strain value
comparedwith asymptomatic subjects with clinical comorbidities
(26%–34%), the authors prespecified the ratio as a 2:1 allocation
ratio, leading to a sample size of nearly 80:40 for c-morbidity and
HFpEF groups, respectively, with a power of 90% and a rate
of 5%. The sample size calculation was performed by using
G∗Power 3.1.5 (University Kiel, Kiel, Germany). Additionally, a
normal control group was included to contrast the difference
from the comorbidity and HFpEF groups. Furthermore, to
eliminate the possible influences of age, BMI, and sex distribution
on visceral adiposity burden, cardiac deformation, and LA
functional measures, we performed a subgroup matching of these
variables and conducted paired comparisons among groups. To
develop a standardized measure on the effects of various kinds of
adiposity (PCF, TAT, AV Groove Fat, and IAF) on cardiac
electromechanical functions, a z score was generated by
subtracting the mean from each adiposity raw data and then
dividing the difference by the SD. A multivariable regression
model was used to determine the significance of the covariate-
adjusted relation between LA deformation data and various
periatrial adiposity, clinical variables, biochemical profiles, and
echocardiography-derived measurements of LV mass with
individual odds ratios, and P values and 95% confidence
intervals (CIs) are reported. Cox proportional hazards ratio on
temporal changes of HF admission rates was performed in our
outpatient cohort, which aimed to explore the association
between adiposity on clinical events, with most echocardiogra-
phy-derived key parameters as confounders.
All data were analyzed with use of the STATA 9.0
software package (StataCorp). The P value was set for 2-tailed
probability with a P value <0.05 considered statistically
significant.
3. Results
3.1. The association between various adiposity measures
and cardiometabolic profiles in subjects who underwent
annual health survey.
The 362 participants (mean age: 51.7±8.9 years old, 31% female
sex) enrolled from annual health evaluation in the first phase of
the study (January 2007–August 2009) were further categorized
Hung et al. Medicine (2016) 95:24 Medicine
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into 3 different groups based on the metabolic scores (0, 1–2,≥3).
Greater metabolic scores were associated with older age, higher
BMI, increased body weight, larger waist circumference, and
higher blood pressures (Supplemental Material, Table 1, all trend
P<0.05, http://links.lww.com/MD/B34). In addition, a variety
of cardiometabolic derangements, including increased fasting
glucose concentrations, higher HbA1c levels, elevated triglycer-
ide levels, greater insulin resistance, lower HDL, and worse renal
function, were all related to higher metabolic scores (all trend P<
0.05). Higher metabolic scores are also associated with greater
amount of body fat composition, visceral adiposity, and more
elevated serum high-sensitivity C-reactive protein (hs-CRP) level
(all trend P<0.05).
Larger amounts of visceral fat (PCF, TAT, AV Groove Fat,
and IAF) were associated with several unfavorable cardiome-
tabolic profiles including greater body weight, elevated BMI,
greater body fat composition, higher systolic blood pressure,
and larger waist circumference (all P<0.05) (Supplemental
Material, Table 2, http://links.lww.com/MD/B34). In addition,
larger AV Groove Fat and IAF were positively associated with
higher triglycerides, HbA1c, insulin resistance (homeostatic
model assessment-insulin resistance [HOMA-IR]), and higher
systemic inflammation marker (hs-CRP), but were inversely
associated with HDL level (all P<0.05). A positive
linear relationship between AV Groove Fat, IAF, and P wave
duration by body surface ECG (r=0.14 and r=0.23 for AV
Groove Fat and IAF, respectively, both P<0.05) was also
observed.
3.2. The feasibility and diagnostic accuracy of various
adiposity measures for MetS
We further explored the clinical cut-off and diagnostic feasibility
of these various sites of adiposity in identifying MetS
(Supplemental Material, Table 3, http://links.lww.com/MD/
B34). The PCF yielded the highest sensitivity (77.8%) (cutoff
value: 76.2mL, area under the receiver-operating characteristic
[AUROC]: 66%, 95% CI: 0.60–0.71), and the IAF showed
relatively high specificity (77.2%) (cutoff value: 6.6cm, AUROC:
64%, 95% CI: 0.58–0.70) in identifying MetS. Meanwhile, IAF
showed highest positive predictive value (39.4%), and PCF
showed highest negative predictive value (89.29%) for MetS
diagnosis.
3.3. Baseline demographic data and visceral adiposity in
healthy, co-morbidity, and HFpEF groups from outpatient
clinic
The study participants from the cardiovascular outpatient clinic
in the phase 2 study (from January 2010 to July 2011) are
reported in Table 1. Compared with healthy and comorbidity
groups, subjects in the HFpEF group tended to be older with a
higher female percentage, had greater BMI, and higher blood
pressure (Table 1, all P<0.05). Subjects in the comorbidity and
HFpEF groups also had higher fasting glucose levels, whereas the
HFpEF group presented with much worse renal function in terms
of lower eGFR, together with higher metabolic scores (all P<
0.05). There was a trend toward higher hs-CRP and brain
Table 1
Baseline demographic information and various visceral adiposity measures in healthy, comorbidity, and HFpEF groups (n=206).
Healthy group Co-morbidity group HFpEF group
(N=40) (N=108) (N=58) P (trend) or X 2
Baseline characters
Age, y 53.95±9.67 55.60±10.49 64.33±12.42
∗,† <0.001
Sex (female), % 16 (40.00%) 35 (32.4%) 31 (53.4%) 0.031
Weight, kg 64.88±10.97 72.42±15.27 70.46±14.25 0.06
BMI, kg/m2 23.59±2.71 26.46±3.94
∗
27.18±3.68
∗
<0.001
Systolic blood pressure, mmHg 117.25±10.81 132.49±16.91
∗
143.53±14.07
∗,† <0.001
Diastolic blood Pressure, mmHg 69.63±8.48 79.54±10.80
∗
78.21±10.54
∗
<0.001
Biochemical data
Fasting glucose, mg/dL 98.28±8.63 114.84±28.28
∗
125.07±49.23
∗
<0.001
Triglyceride, mg/dL 119.08±66.55 140.33±81.22 124.78±65.90 0.716
HDL, mg/dL 50.84±13.05 47.84±14.75 44.55±12.60 0.005
eGFR, mL/min/1.73m2 97.56±13.10 92.97±25.50 77.89±17.70
∗,† <0.001
Metabolic score 0.97±1.04 2.27±1.26
∗
2.61±0.98
∗,† <0.001
hs-CRP, mg/dL (median, 25th–75th) 0.087 (0.04–0.13) 0.19 (0.1–0.35)
∗
0.35 (0.12–0.91)
∗,† <0.001
BNP (median, 25th–75th) 33.8 (15.8–50.5) 44.5 (20.9–61) 264.4 (226.1–320)
∗,† <0.001
Medical history
Hypertension history, % 0 (0%) 83 (76.9%) 43 (74.1%) <0.001
Diabetes history, % 0 (0%) 32 (29.6%) 19 (32.8%) <0.001
Hyperlipidemia history, % 0 (0%) 45 (44.1%) 33 (66%) <0.001
Cardiovascular disease, % 0 (0%) 24 (22.2%) 8 (13.8%) 0.004
Various adiposity measures
Body fat composition, % 25.4±7.6 30.7±7.6
∗
35.1±8.4
∗,† <0.001
PCF, mL 59.8±21.4 79.7±32.2
∗
94.9±34.7
∗,† <0.001
TAT, mL 6.49±3.59 8.73±4.94
∗
8.95±5.54
∗
0.0282
AV groove fat, mm 9.72±3.88 13±5.65
∗
16.13±6.71
∗,† <0.001
IAF, mm 6.58±1.78 8.44±2.6
∗
9.82±2.85
∗,† <0.001
AV Groove=atrioventricular groove, BMI=body mass index, BNP=brain natriuretic peptide, eGFR=estimated glomerular filtration rate, HDL=high density apolipoprotein, HFpEF=heart failure with preserved
ejection fraction, hs-CRP=high sensitivity C-reactive protein, IAF= inter-atrial fat, PCF=pericardial fat, TAT= thoracic periaortic.
∗
P<0.05 compared to healthy group.
† P<0.05 compared to comorbidity group.
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natriuretic peptide levels in both the comorbidity and HFpEF
groups (both P<0.05). We also observed that there was a graded
increase in body fat composition, PCF, AV Groove Fat, and IAF
across healthy, comorbidity, and HFpEF groups (all ANOVA
P<0.05), and subjects with higher metabolic scores consistently
showed greater visceral adiposity (Fig. 2, all P<0.05). An age-,
sex-, and BMI-matched study subgroup from the same cohort
(total n=162: n=27, n=95, and n=40 in healthy, co-morbidity,
and HFpEF groups, respectively) showed similar increase of
visceral adiposity across the 3 groups, with AV Groove Fat and
Figure 2. Comparisons of various adiposity measures among different metabolic score (MS) groups. Higher MSs were associated with a greater amount of various
visceral adiposities accumulation, which is significantly larger in subjects with diagnosed metabolic syndrome compared with those with a smaller MS.
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IAF differing substantially between comorbidity and HFpEF
groups (Supplemental Material, Table 4, http://links.lww.com/
MD/B34). Finally, a greater proportion of hypertension, diabetes
mellitus, cardiovascular diseases, and medication use for
hyperlipidemia was observed in both the comorbidity and
HFpEF groups (all P<0.05).
3.4. Baseline echocardiography indices in healthy,
comorbidity, and HFpEF groups from outpatient clinic
Both comorbidity and HFpEF groups shared common features of
cardiac phenotypic patterns, including greater LV wall thickness,
larger LV mass, and greater degree of LV concentricity, although
subjects categorized as HFpEF presented with smaller LV
volumes (all P<0.05) (Table 2). Diastolic function parameters
appeared to be worse in both the comorbidity and HFpEF
groups, with the HFpEF group demonstrating a greater degree of
impaired LV diastolic relaxation, and higher LV filling pressures
(both P<0.05). Our study demonstrated that HFpEF groups had
largest LA volumes and worst LA strains (–11.07% compared
with comorbidity, P<0.001), and the HFpEF group further
showed a greater degree of LA stiffness (all P<0.05). We also
observed that both the comorbidity and HFpEF groups had
similarly worsening longitudinal strain (–18.49% vs –15.7%,
P<0.001), and the HFpEF group further showed reduction in
circumferential and radial strain when compared with the
comorbidity and healthy groups (all P<0.05). Finally, the trend
toward various worse cardiac deformations and LA structural/
functional measures remained unchanged among groups after
age, sex, and BMI matching (Supplemental Material, Table 4,
http://links.lww.com/MD/B34).
3.5. The association between various adiposity measures
and LA electromechanical parameters in healthy,
comorbidity, and HFpEF groups from outpatient clinic
We observed that greater accumulation of various visceral
adiposity measures (PCF, TAT, AV Groove Fat, and IAF,
respectively) and greater body fat composition were inversely
associated with LA mechanical function in terms of worsening
strain (r=–0.4, –0.31, –0.31, –0.44, and –0.27 for PCF, TAT,
AV Groove Fat, IAF and body fat composition, respectively,
all P<0.001). A strong and consistent link between unfavorable
LA electromechanical parameters and greater visceral fat
deposits was shown, especially those in anatomic areas adjacent
to the LA chamber (such as AV Groove Fat and IAF) after
accounting for clinical covariates and profiles of MetS (Table 3,
all P<0.05). For each standardized unit increase of IAF,
there was consistent reduction of LA strain (b-coef: –0.28,
95% CI: –0.42 to –0.15), increase of LA stiffness (b-coef: 0.23,
95% CI: 0.1–0.36), and more prolonged P wave duration
(b-coef: 0.23, 95% CI: 0.09–0.36 (all P<0.05). Further, there
was a trend toward greater corrected QT interval, P wave
duration across healthy, comorbidity, and HFpEF groups
(Supplemental Material, Table 5, P for trend <0.05, http://
links.lww.com/MD/B34).
Table 2
Baseline echocardiography parameters in healthy, co-morbidity, and HFpEF groups (n=206).
Healthy group Comorbidity group HFpEF group
Echocardiography measures (N=40) (N=108) (N=58) P (trend)
Conventional echo parameters
IVS, mm 9±1.13 10.12±1.54
∗
10.74±1.27
∗,† <0.001
LVPW, mm 8.96±1.1 9.96±1.23
∗
10.79±1.33
∗,† <0.001
LVEDV, mL 70.2±15.6 74.6±20.1 66.1±16.1† <0.001
LVESV, mL 26.45±7.03 27.53±8.71 24.96±8.11† 0.397
LVEF, % 63.63±5.72 63.5±5.46 62.09±6.34 0.238
RWT, % 39.8±5.2 43.1±7.1 46.9±6.4
∗
<0.001
LV mass, g 135.79±28.17 167.75±34.93
∗
178.58±39.97
∗,† <0.001
LV mass index, g/m2 72.72±13.59 85.85±15.53
∗
90.86±20.67
∗,† <0.001
LV mass-to-volume ratio 1.92±0.68 2.1±0.66
∗
2.79±0.94
∗,† <0.001
Doppler indices
Mitral E DT, ms 199.85±51.48 232.39±49.06
∗
234.43±64.27
∗,† 0.004
Mitral IVRT, ms 82.86±15.94 99.7±18.6
∗
85.81±16.86† 0.476
Mitral inflow E, cm/s 69.77±15.9 66.06±14.58
∗
77.32±21.9
∗,† 0.037
TDI E’, cm/s 9.61±2.03 7.82±2.07
∗
5.86±1.9
∗,† <0.001
E/E’, mmHg 7.54±2.3 9.07±3.59 16.29±6.33
∗,† <0.001
Left atrial indices
LA volume (max), mL 30.5±7.6 43±8.2
∗
58.2±11.2
∗,† <0.001
LA volume (min), ml 14±4 20.4±5.1
∗
31.3±9.6
∗,† <0.001
LA strain, % 46.3±9.6 39.2±8.5
∗
28.2±6.4
∗,† <0.001
LA stiffness, mmHg % 0.17±0.05 0.24±0.1 0.61±0.29
∗,† <0.001
Deformation parameters
Longitudinal strain, % 19.86±1.73 18.49±1.67 15.7±1.82∗,† <0.001
Circumferential strain, % 31.97±4.34 30.49±4.82 27.42±5.33∗,† <0.001
Radial strain, % 43.78±12.33 40.04±11.81 29.11±7.8
∗,† <0.001
LV twist, degree 11.36±3.26 12.99±3.22 11.08±2.74 0.674
DT= transmitral E-wave deceleration time, E=early mitral inflow diastolic velocity, E’=early mitral annular relaxation velocity, IVRT= iso-volumic relaxation time, IVS= inter-ventricular septum, LA= left atrial/left
atrium, LV= left ventricular/left ventricle, LVPW= left ventricular posterior wall, S= strain.
∗
P<0.05 compared to healthy group.
† P<0.05 compared to comorbidity group.
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3.6. Risk stratification based on IAF adiposity measures in
healthy, comorbidity, and HFpEF groups from outpatient
clinic
Over a median 1017.8 days of follow-up (25th-75th: 683.5-1505
days), 29 subjects experienced HF-related hospitalization or
death. We observed that larger IAF adiposity was related to
higher incidence of HF hospitalization (hazard ratio [HR]: 3.71,
95% CI: 1.58–8.71), which remained significantly higher after
adjusting for age, sex, and various echocardiography-derived
parameters, including LV strain, LV mass index, and LV filling
pressure as well as LA volumes (all P<0.05). IAF above the
median level (≥8.2mm) carried nearly 4 times greater chance
(HR: 4.11, 95%CI: 1.5–11.32, log rank P<0.05) (Supplemental
Material, Figure 1, http://links.lww.com/MD/B34) of having HF
hospitalization even after adjusting age, sex, and LV mass index
in survival model (Figure 3 & Supplemental Material, Table 6,
http://links.lww.com/MD/B34). For the age-, sex-, and BMI-
matched subgroup in the current work (n=162), per standard-
ized increase of IAF was associated with higher risk of HF
hospitalization (HR: 2.67, 95% CI: 1.74–4.09, P<0.001),
which remained statistically significant after accounting for those
echocardiography-derived evaluations.
4. Discussion
In our study, we showed that greater visceral adiposity measures
were associated with unfavorable anthropometrics, worse car-
diometabolic profiles, higher insulin resistance, and a greater
degree of systemic inflammation. In addition, accumulation of
visceral adipose deposits was related to certain cardiac remodeling
and functional asynergy. Specifically, those fat deposits surround-
ing the atria were more relevant to LA electromechanical
disturbances in terms of lower LA strain, higher LA stiffness,
and interatrial conduction disturbances, which remained indepen-
dent after accounting for baseline clinical covariates or medical
histories.Wealso demonstrated that subjectswithHFpEF featured
an excessive burden of visceral adiposity, which may confer a
higher risk for HF hospitalization during clinical follow-up.
Accumulating evidence supports the strong association of
diabetes and obesity[23] with HF incidence; those with MetS[24]
had higher rates of HF hospitalization.[10] On one hand, MetS,
defined as a constellation of several clinical components with a
characteristic component of central obesity, is strongly linked
to coronary artery disease [25] and HF.[10] On the other hand,
the existence of MetS and insulin resistance as the relevant
central factor has also been reported to mediate unbalanced
Table 3
The associations between various adiposity measures and LA electromechanical parameters in Healthy, comorbidity, and HFpEF Groups
(n=206).
LA strain, % LA stiffness index P duration (corrected)
Adiposity Measures ß-coef. P ß-coef. P ß-coef. P
Univariate model
Body fat composition, % 0.274 <0.001 0.227 0.005 0.206 0.009
PCF, mL 0.407 <0.001 0.353 <0.001 0.224 0.001
TAT, mL 0.309 <0.001 0.223 0.003 0.152 0.032
AV groove fat, mm 0.348 <0.001 0.343 <0.001 0.332 <0.001
IAF, mm 0.443 <0.001 0.416 <0.001 0.41 <0.001
Multivariate model 1
Body fat composition, % 0.269 <0.006 0.203 0.006 0.201 0.006
PCF, mL 0.373 <0.001 0.282 <0.001 0.174 0.008
TAT, mL 0.305 <0.001 0.203 0.002 0.154 0.023
AV groove fat, mm 0.309 <0.001 0.285 <0.001 0.299 <0.001
IAF, mm 0.41 <0.001 0.341 <0.001 0.367 <0.001
Multivariate model 2
Body fat composition, % 0.071 0.371 0.08 0.326 0.064 0.425
PCF, mL 0.218 0.006 0.206 0.008 0.034 0.673
TAT, mL 0.103 0.246 0.16 0.063 0.006 0.964
AV groove fat, mm 0.232 <0.001 0.266 <0.001 0.225 <0.001
IAF, mm 0.33 <0.001 0.307 <0.001 0.286 <0.001
Multivariate model 3
Body fat composition, % 0.078 0.306 0.037 0.632 0.027 0.724
PCF, mL 0.138 0.08 0.122 0.11 0.049 0.529
TAT, mL 0.054 0.536 0.083 0.333 0.065 0.0449
AV groove fat, mm 0.157 0.02 0.213 0.001 0.169 0.01
IAF, mm 0.264 <0.001 0.265 <0.001 0.241 <0.001
Multivariate model 4
Body fat composition, % 0.073 0.338 0.051 0.525 0.032 0.674
PCF, mL 0.138 0.077 0.151 0.047 0.035 0.642
TAT, mL 0.07 0.412 0.129 0.123 0.04 0.632
AV groove fat, mm 0.166 0.014 0.211 0.002 0.174 0.008
IAF, mm 0.284 <0.001 0.227 0.001 0.225 0.001
Model 1: adjusted for age; Model 2: adjusted for age, sex, body mass index; Model 3: adjusted for age, sex, body mass index, systolic blood pressure, hypertension, diabetes, coronary artery disease, LV mass and
eGFR; Model 4: adjusted for age, sex, body mass index, systolic blood pressure, LV mass, eGFR, and metabolic scores. AV Groove=atrioventricular groove, HFpEF=heart failure with preserved ejection fraction,
IAF= inter-atrial fat, LA= left atrial/left atrium, PCF=pericardial fat, TAT= thoracic periaortic.
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sympathovagal tone and regarded as proarrhythmic, in part
driven by augmented oxidative stress, altered oxido-redox status,
or regulative channels effect on ions, leading to altered
electromechanical properties, higher rate of arrhythmia recur-
rence, and worse cardiovascular outcomes.[26–28] Oxidative
stress itself had also been reported to play a role in regulating
cardiac sympathetic innervations defect in HF, which further
potentiate arrhythmia formation.[29] Although the exact mecha-
nisms underlying HF development in subjects with MetS remain
unclear, a complex interplay of a variety factors and potential
Figure 3. The schematic illustrations represented the location and assessment of various visceral adiposities surrounding cardiac structures (A, B), as well as the
potential mechanisms and links among regional visceral adiposity measures, clinically observed metabolic derangements, elicited inflammation, and cardiac
remodeling (C). The speculated mechanism of interatrial fat and associated left atrial cardiac electromechanical disturbances was also demonstrated.
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pathogenesis are possibly involved (Supplemental Material,
Figure 2, http://links.lww.com/MD/B34).[8–10]
Central obesity or visceral adiposity, rather than subcutaneous
or peripheral fat deposits, shows a consistent correlation with
systemic inflammation and metabolic derangements, and had
recently been regarded as the “key” biological sources of
proinflammatory pathways and related adverse effects.[13–15] So
far, a variety of biomarkers, including brain natriuretic peptide
family and insulin-like growth factor-I, have all been reported for
HF risk stratification.[30] Furthermore, circulating blood glucose,
insulin resistance,[31,32] and elevated inflammatory markers (e.g.,
interleukin-6 or hs-CRP) from systemic metabolic derangements
were proposed to be associated with cardiac remodeling and
redundant LV mass (Supplemental Material, Figure 2, http://
links.lww.com/MD/B34).[23] The term “cardiac steatosis” has
recently been proposed to describe excessive myocardial
triglyceride uptake, overflow of intramyocardial free fatty acids,
enhanced beta oxidation, and a higher degree free radical
accumulation within cardiomyocytes in diabetic subjects with
HF,[33–35] and further enhance oxidative stress and cardiac
fibrosis (Fig. 3 A–C). Previous0 studies revealed that microvas-
cular endothelial inflammation in metabolic derangements,
rather than hemodynamic load, may further aggravate patho-
logic interstitial fibrosis andHF.[36] Based on these findings, it has
been proposed that visceral fat deposits could be biologically
active and may exert cardiotoxic effects on adjacent cardiac
structures, leading to cardiac functional deterioration.[37,38] In
this regard, HFpEF as a clinically distinct phenotype from
reduced ejection fraction HF had been shown to be more relevant
to such metabolic derangements and molecular proinflammatory
signaling pathways.[31–36] In accordance to previous data, our
HFpEF group in the second-phase study indeed presented greater
BMI and higher insulin resistance, as well as excessive visceral
adiposity and more exaggerated systemic inflammation.
The same pathogenetic mechanisms underlying LV can also be
applicable to LA. LA functional decline as well as structural
remodeling or dilation may occur in subjects with HF and
elevated cardiac filling pressures.[39] However, LA fibrosis or
remodeling secondary to comorbidities including hypertension,
diabetes, obesity, or ischemia may pathologically resemble LV
subendocardial damage though inflammatory responses inde-
pendent of elevated filling pressures.[33,40–42] Such LA fibrotic
changes may lead to increased LA stiffness with concomitant
mechanical failure, leading to “stiff LA syndrome,” which could
be more evident in HFpEF when compared to those with
hypertensive hypertrophy.[4,5] By utilizing deformationmeasures,
we are now capable of identifying LA functional abnormalities
without volume expansion or remodeling in subjects with HF.
Furthermore, the disease entity “lipomatous hypertrophy” and
findings from several large epidemiological studies have shown
that altered LA electrical properties or conduction disturbances
were associated with excessive PCF,[43] which may also result in
initiation and perpetuation of AF.[18,44–45] Taken together, these
data may indicate that IAF accumulation may also impede
interatrial conduction at a later stage, which may be partly driven
by its anatomic proximity to specialized interatrial conduction
fibers (Fig. 3 D). Of note, although body fat composition is a
commonly used clinical tool for total body adiposity assess-
ment,[46] we showed in our work that its association with LA
electromechanical indexes became markedly attenuated after
accounting for BMI. This finding may also support our
speculations that regional adiposity burden may differ from
global fat assessment in several biological behaviors.
We therefore speculate that IAF may be an alternative, new,
and representative surrogate marker of visceral fat in addition to
the pericardial adiposity measure, as the latter assessment
remains exclusively confined to pericardial sac with minimal
expansion capacity during clinical progression of metabolic
derangements in the same individual. Finally, we show in our
work that such visceral adipose tissue is readily assessable using
noninvasive imaging methods, which are more practical for
clinical use in daily practice.
4.1. Limitations
A number of limitations may exist in our current work. First, our
findings are cross-sectional. Despite our inability to establish
causal relationship from our data, we believe that these findings
could supplement observations withmetabolic derangements and
obesity as a major clinical risk in the pathogenesis of HF,
especially for those with HFpEF. Therefore, the real causes and
cause–effect relationship between IAF deposits andworsening LA
electromechanical function may warrant further investigations.
In addition, comparisons of these visceral fat depots between
more “diseased” individuals and a healthy control group with
clinically fully matched baseline demographics (such as age or
body size in terms of BMI) may be difficult, and the real effect of
visceral adiposity on cardiac functions and its prognostic value
will have to be interpreted with caution in our current work.
Therefore, further work may be helpful to solve these puzzles.
Finally, while the somewhat different recruiting periods in
various study phases might induce a bias in the patients’ selection,
though there were no major changes in our clinical practice and
settings during these study periods.
5. Conclusion
Greater visceral adiposity measures are positively correlated with
several cardiometabolic derangements, insulin resistance, and
elicited inflammatory response. In addition, subjects with known
clinical cardiovascular risks or diagnosed HFpEF were prone to
present with greater degrees of visceral adiposity and higher
degree of metabolic abnormalities. Excessive accumulation of
visceral adiposity, especially IAF deposition, may likely mediate
several adverse biological effects or pathologies, resulting in a
broad spectrum of LA electromechanical disturbances. Finally,
greater accumulation of such visceral adiposity was also related
to higher rates of HF hospitalization.
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